Natera partners with TransCode. JPMorgan lifts target for Natera stock to USD 460

Published on 10/15/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera posted USD 753 million in Q2 2026 revenue against USD 661.24 million consensus. Natera stock costs EUR 353.35 on October 15, 2026.

Clinical and financial markers

Natera and TransCode announced their Phase 2a collaboration on October 13, 2026.
Natera reported USD 753 million in second-quarter 2026 revenue against USD 661.24 million consensus.
Natera stock traded at EUR 353.35 at 9:42 a.m. CEST at Lang & Schwarz on October 15, 2026.
JPMorgan raised its Natera price target to USD 460 on October 14, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) entered a colorectal cancer trial collaboration with TransCode on October 13, 2026, while JPMorgan raised its target for Natera stock to USD 460 on October 14, 2026. The partnership will use Natera's Signatera test to identify molecular residual disease positive patients for a Phase 2a study.

Collaboration targets trial enrollment

According to BioSpace on October 13, 2026, TransCode will use Signatera to identify patients who remain positive for molecular residual disease after curative-intent treatment. The trial evaluates TTX-MC138 in colorectal cancer and is being conducted within the PRE-I-SPY program.

The measurable commercial link is patient identification rather than a disclosed contract value. For Natera, the collaboration extends Signatera's role from disease monitoring into trial recruitment, with eligibility tied to molecular evidence and no radiographic evidence of disease.

What does the financial base show?

Natera's second-quarter 2026 revenue reached USD 753 million, compared with USD 661.24 million consensus, according to MarketBeat. The company also raised its full-year 2026 revenue guidance to USD 2.85 billion to USD 2.91 billion during the earnings call, as reported by Benzinga on October 12, 2026.

Three events shape the story

On August 6, 2026, Natera reported USD 753 million in second-quarter revenue. On October 9, 2026, Natera received FDA Breakthrough Device designation for its multi-cancer early detection assay, according to Natera. On October 13, 2026, the company announced the TransCode collaboration for a Phase 2a colorectal cancer trial.

On October 14, 2026, JPMorgan raised its Natera price target from USD 360 to USD 460 and kept an overweight rating, according to TranscriptDaily. The next substantiated event date is the October 13 collaboration announcement, while the latest reported financial period is the second quarter of 2026.

Stock stays in active trading

Natera stock was trading at EUR 353.35 at Lang & Schwarz on October 15, 2026 at 9:42 a.m. CEST. The quote puts the German trading perspective alongside a Nasdaq-listed diagnostics company whose latest reported quarter delivered USD 753 million in revenue and a raised USD 2.85 billion to USD 2.91 billion full-year revenue outlook. The further course of trading is shown by the continuously updated real-time quote of Natera stock.